- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 Inhibition: From Current Advances to Evolving Future
Authors
Keywords
-
Journal
Cells
Volume 11, Issue 19, Pages 2972
Publisher
MDPI AG
Online
2022-09-26
DOI
10.3390/cells11192972
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
- (2022) Shakir Ahamad et al. DRUG DISCOVERY TODAY
- AZD8233 Antisense Oligonucleotide targeting PCSK9 does not prolong QT interval AZD8233 ASO C‐QT analysis
- (2022) Dinko Rekić et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
- (2022) Stephen J. Nicholls et al. JACC-Cardiovascular Imaging
- PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
- (2022) Arianna Toscano et al. Biomolecules
- PCSK9 mediates the oxidative low‑density lipoprotein‑induced pyroptosis of vascular endothelial cells via the UQCRC1/ROS pathway
- (2021) Junfa Zeng et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Humanized Mice as a Tool to Study Sepsis—More Than Meets the Eye
- (2021) Krzysztof Laudanski INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
- (2021) Juanjuan Yuan et al. Protein & Cell
- In vivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system
- (2021) Qian Li et al. Molecular Therapy-Methods & Clinical Development
- Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis
- (2021) Yimo Zhou et al. Frontiers in Cardiovascular Medicine
- In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
- (2021) Kiran Musunuru et al. NATURE
- In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
- (2021) Tanja Rothgangl et al. NATURE BIOTECHNOLOGY
- New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice
- (2021) Ningning Ma et al. PHARMACOLOGICAL RESEARCH
- An oral antisense oligonucleotide for PCSK9 inhibition
- (2021) Peter Gennemark et al. Science Translational Medicine
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
- (2021) Anindita Bhattacharya et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- PCSK9 vaccine: so near, yet so far!
- (2021) Amirhossein Sahebkar et al. EUROPEAN HEART JOURNAL
- Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways
- (2021) Vittoria Cammisotto et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
- (2021) Amir Abbas Momtazi-Borojeni et al. Vaccines
- PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling
- (2021) Valentina Scalise et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility.
- (2020) Frederick J. Raal et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α
- (2020) Xuelei Wang et al. EBioMedicine
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- (2020) Nicholas A. Marston et al. CIRCULATION
- Evaluation of the Potential Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Niemann–Pick Disease, Type C1
- (2020) Niamh X. Cawley et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
- (2020) Brian A. Bergmark et al. JAMA Cardiology
- PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
- (2020) Vittoria Cammisotto et al. Antioxidants
- Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock
- (2020) Mihir R. Atreya et al. CRITICAL CARE MEDICINE
- PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study
- (2020) A. Vecchié et al. JOURNAL OF INTERNAL MEDICINE
- Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress
- (2020) Leila Safaeian et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
- (2020) Zhiyong Qi et al. CIRCULATION
- Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department
- (2020) Francesca Innocenti et al. CLINICAL AND EXPERIMENTAL MEDICINE
- An Update on the Role of PCSK9 in Atherosclerosis
- (2020) Ece Yurtseven et al. Journal of Atherosclerosis and Thrombosis
- Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
- (2020) Esther Shuyi Gan et al. JOURNAL OF CLINICAL INVESTIGATION
- PCSK9: A Potential Therapeutic Target for Sepsis
- (2020) Yuan Yuan et al. Journal of Immunology Research
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
- (2019) I. Dicembrini et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
- (2019) Amir Abbas Momtazi-Borojeni et al. ATHEROSCLEROSIS
- Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases
- (2019) Madalyn Brown et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Reduced plasma PCSK 9 response in patients with bacteraemia is associated with mortality
- (2019) Juha Rannikko et al. JOURNAL OF INTERNAL MEDICINE
- Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients
- (2019) Alex K. K. Leung et al. Scientific Reports
- Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection
- (2019) Jérôme Caron et al. Stem Cell Research & Therapy
- PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects
- (2019) Siripong Palee et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines
- (2019) Shijie Liu et al. CARDIOVASCULAR RESEARCH
- Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
- (2019) Amir Abbas Momtazi-Borojeni et al. BMC Medicine
- Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials
- (2018) Yang Wang et al. American Journal of Cardiovascular Drugs
- PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
- (2018) Merel L. Hartgers et al. Journal of Clinical Lipidology
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
- (2018) Paul M Ridker et al. Journal of Clinical Lipidology
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Mendelian randomization study of the effects of blood lipids on breast cancer risk
- (2018) Christoph Nowak et al. Nature Communications
- Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor
- (2018) Peter M. Grin et al. Scientific Reports
- Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
- (2018) Makan Khoshnejad et al. MOLECULAR THERAPY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
- (2017) Marianne Benn et al. BMJ-British Medical Journal
- MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunopathology and immunosuppression
- (2017) Christopher R. Shaler et al. PLOS BIOLOGY
- Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
- (2017) Marianne Benn et al. BMJ-British Medical Journal
- CRISPR-Cas9 Targeting ofPCSK9in Human Hepatocytes In Vivo—Brief ReportSignificance
- (2016) Xiao Wang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
- (2016) Jin M. Cheng et al. ATHEROSCLEROSIS
- Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
- (2016) Hagai Tavori et al. CARDIOVASCULAR RESEARCH
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- Platelet-Mediated Thrombosis
- (2016) Paul A. Gurbel et al. CIRCULATION RESEARCH
- Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis
- (2016) Keith R. Walley Current Opinion in Critical Care
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis
- (2016) John H. Boyd et al. Journal of Innate Immunity
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis
- (2016) Dhruva J. Dwivedi et al. SHOCK
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
- (2014) Qiurong Ding et al. CIRCULATION RESEARCH
- Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9
- (2014) Kévin Ly et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
- (2014) Hassan Kassassir et al. Pharmacological Reports
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- (2013) Michael J. Koren et al. CIRCULATION
- Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
- (2013) Yingnan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics
- (2013) Pedro M. R. Cruz et al. Frontiers in Pharmacology
- PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
- (2012) Kai Kysenius et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- Antisense oligonucleotides for the treatment of dyslipidaemia
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
- (2011) Paola Lo Surdo et al. EMBO REPORTS
- Regulatory Effects of Peptides from the Pro and Catalytic Domains of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) on Low-Density Lipoprotein Receptor (LDL-R)
- (2010) H. Palmer-Smith et al. CURRENT MEDICINAL CHEMISTRY
- A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
- (2010) Taichi Yamamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
- (2008) Guoqing Cao et al. Endocrine Metabolic & Immune Disorders-Drug Targets
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started